Previous Close | 9.32 |
Open | 9.29 |
Bid | 9.01 x 800 |
Ask | 9.35 x 900 |
Day's Range | 9.07 - 9.42 |
52 Week Range | 6.87 - 13.66 |
Volume | |
Avg. Volume | 222,557 |
Market Cap | 392.42M |
Beta (5Y Monthly) | 0.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.77 |
Earnings Date | Mar 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 27, 2010 |
1y Target Est | 17.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AXGN
ALACHUA, Fla. and TAMPA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2022 revenue. Preliminary Unaudited Fourth Quarter and Year-End Performance and Business Highlights Fourth quarter revenue is expected to be approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the imp
Study concluded allograft and autograft repairs delivered significantly better rates of meaningful sensory recovery in short gaps as compared to conduit repairs in a systematic meta-analysis including over 1,500 nerve repairs across 35 studiesALACHUA, Fla. and TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the independent publication of a comprehen
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 41st Annual Healthcare Conference in San Francisco. The presentation is scheduled for Thursday, January 12, 2023 at 9:45 a.m. PST (12:45 p.m. EST). The presentation will be webcast live and accessible thro